BioLine RX Ltd
BLRX4.220USD
+0.120+2.93%
종가 06/03, 16:00（ET）시세는 15분 지연됩니다
5.64B시가총액
손실P/E TTM
자세한 내용은 BioLine RX Ltd 회사
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
회사 정보
회사 코드BLRX
회사 이름BioLine RX Ltd
상장일Jan 30, 2007
설립일2003
CEOMr. Philip Adam (Phil) Serlin
직원 수28
유형Ordinary Share
회계 연도 종료Jan 30
주소Modi'in Technology Park
도시MODIIN
증권 거래소Tel Aviv Stock Exchange
국가Israel
우편 번호7177871
전화97286429100
웹사이트https://www.biolinerx.com/
회사 코드BLRX
상장일Jan 30, 2007
설립일2003
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Dr. Barbara-Jean (BJ) Bormann
Dr. Barbara-Jean (BJ) Bormann
Director
Director
--
--
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주주
업데이트 시간: Sat, May 17
업데이트 시간: Sat, May 17
주주 통계
유형
주주 통계
주주
비율
Hong Seng Technology Ltd
4.59%
Intracoastal Capital, L.L.C.
0.08%
Wells Fargo Advisors
0.08%
BNP Paribas Securities Corp. North America
0.05%
Rhumbline Advisers Ltd. Partnership
0.04%
Other
95.16%
주주 통계
주주
비율
Hong Seng Technology Ltd
4.59%
Intracoastal Capital, L.L.C.
0.08%
Wells Fargo Advisors
0.08%
BNP Paribas Securities Corp. North America
0.05%
Rhumbline Advisers Ltd. Partnership
0.04%
Other
95.16%
유형
주주
비율
Corporation
4.67%
Research Firm
0.17%
Investment Advisor
0.08%
Investment Advisor/Hedge Fund
0.01%
Other
95.07%
기관 주식 보유
업데이트 시간: Sat, Feb 22
업데이트 시간: Sat, Feb 22
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
63
215.61K
5.79%
-104.86K
2024Q4
63
222.04K
6.08%
+67.69K
2024Q3
62
233.17K
7.79%
-25.85K
2024Q2
66
277.79K
10.04%
+89.80K
2024Q1
64
205.72K
6.62%
+27.03K
2023Q4
67
200.88K
6.35%
-8.70K
2023Q3
69
34.99K
2.17%
-169.90K
2023Q2
63
31.93K
2.08%
-207.57K
2023Q1
65
80.66K
5.25%
-259.21K
2022Q4
64
168.22K
10.94%
-244.43K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Hong Seng Technology Ltd
170.73K
4.59%
+170.73K
--
Oct 09, 2023
BNP Paribas Securities Corp. North America
1.43K
0.04%
+1.43K
--
Dec 31, 2024
Rhumbline Advisers Ltd. Partnership
1.07K
0.03%
+259.00
+31.78%
Dec 31, 2024
Morgan Stanley & Co. LLC
1.98K
0.05%
-2.78K
-58.44%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Mon, Jun 2
업데이트 시간: Mon, Jun 2
이름
비율
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
날짜
유형
비율
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
